Cleary Ryan K, Meshman Jessica, Dewan Michael, Du Liping, Cmelak Anthony J, Luo Guozhen, Morales-Paliza Manuel, Weaver Kyle, Thompson Reid, Chambless Lola B, Attia Albert
Department of Radiation Oncology, Vanderbilt University Medical Center.
Department of Neurological Surgery, Vanderbilt University Medical Center.
Cureus. 2017 May 26;9(5):e1279. doi: 10.7759/cureus.1279.
Introduction Stereotactic radiosurgery (SRS) is increasingly used as an alternative to whole brain radiotherapy (WBRT) following surgical resection of brain metastases. We analyzed the outcomes of postoperative frameless fractionated stereotactic radiosurgery (fSRS) cases for surgically resected brain metastases at our institution. Materials and Methods We performed a retrospective review of 85 patients who underwent fSRS to 87 resection beds from 2006 - 2014 with a median follow-up of 6.4 months. Clinically relevant outcomes were assessed with analysis to determine predictors of these outcomes. Results The median target volume was 9.8 cm- (1.1 - 43.1 cm-). The most frequently used fractionation scheme was 3,000 cGy in five fractions. The rates of local control (LC), distant brain failure (DBF), and overall survival (OS) at one-year were 87%, 52%, and 52%, respectively. Five patients (5.9%) experienced Grade >2 toxicity related to fSRS, including seizures (two), symptomatic radionecrosis (two), and potential treatment-related death (one). A multivariable analysis revealed that tumor volume (p < 0.001) and number of fractions (p < 0.001) were associated with LC, while recursive partitioning analysis (RPA) class (< .0001), tumor volume (= .0181), and the number of fractions (.0181) were associated with OS. Conclusions Postoperative fSRS for surgically resected brain metastases is well-tolerated and achieves durable LC. Further studies are needed to determine the optimal dose and fractionation for fSRS as well as to compare outcomes with WBRT.
立体定向放射外科(SRS)越来越多地被用作脑转移瘤手术切除后全脑放疗(WBRT)的替代方法。我们分析了我院接受术后无框架分次立体定向放射外科(fSRS)治疗的手术切除脑转移瘤病例的结果。
我们对2006年至2014年期间接受fSRS治疗87个切除床的85例患者进行了回顾性研究,中位随访时间为6.4个月。通过分析评估临床相关结果,以确定这些结果的预测因素。
中位靶体积为9.8 cm³(1.1 - 43.1 cm³)。最常用的分割方案是5次分割,每次3000 cGy。一年时的局部控制(LC)率、远处脑衰竭(DBF)率和总生存率(OS)分别为87%、52%和52%。5例患者(5.9%)出现与fSRS相关的2级以上毒性反应,包括癫痫发作(2例)、症状性放射性坏死(2例)和可能的治疗相关死亡(1例)。多变量分析显示,肿瘤体积(p < 0.001)和分割次数(p < 0.001)与LC相关,而递归分区分析(RPA)分级(< 0.0001)、肿瘤体积(= 0.0181)和分割次数(0.0181)与OS相关。
手术切除脑转移瘤后行术后fSRS耐受性良好,可实现持久的局部控制。需要进一步研究以确定fSRS的最佳剂量和分割方式,并将结果与WBRT进行比较。